Chemical Engineering @ChemengFiles.Com

2009 is the year of the 40th anniversary since the introduction of the first global flow cytometer based on fluorescence, the ICP 11.

Currently, the German biotechnology company Partec celebrates anniversary in Saxonia State Wackerbarth Vineyard Castle near Dresden. For the festive ceremony, the director Roland Göhde receive 100 guests from the scientific, economic and political.

2009 is the year of the 40th anniversary since the introduction of the first global flow cytometer based on fluorescence, the ICP 11.

Currently, the German biotechnology company Partec celebrates anniversary in Saxonia State Wackerbarth Vineyard Castle near Dresden. For the festive ceremony, the director Roland Göhde receive 100 guests from the scientific, economic and political.

Amira Pharmaceuticals, Inc. announced it will present preclinical data on its program of LPA1 receptor antagonist on June 30, 2009 in the summer research conference of the Federation of American Societies for Experimental Biology (FASEB) held in Carefree, Arizona.

The LPA1 receptor is part of the phosphatidic acid path / lisofosfatidilcolina, which among other things is associated with the communication from cell to cell. In recent studies, it has been shown to play a role in fibrotic disease, particularly idiopathic pulmonary fibrosis (IPF).

Amira Pharmaceuticals, Inc. announced it will present preclinical data on its program of LPA1 receptor antagonist on June 30, 2009 in the summer research conference of the Federation of American Societies for Experimental Biology (FASEB) held in Carefree, Arizona.

The LPA1 receptor is part of the phosphatidic acid path / lisofosfatidilcolina, which among other things is associated with the communication from cell to cell. In recent studies, it has been shown to play a role in fibrotic disease, particularly idiopathic pulmonary fibrosis (IPF).

Amira Pharmaceuticals, Inc. announced it will present preclinical data on its program of LPA1 receptor antagonist on June 30, 2009 in the summer research conference of the Federation of American Societies for Experimental Biology (FASEB) held in Carefree, Arizona.

The LPA1 receptor is part of the phosphatidic acid path / lisofosfatidilcolina, which among other things is associated with the communication from cell to cell. In recent studies, it has been shown to play a role in fibrotic disease, particularly idiopathic pulmonary fibrosis (IPF).

Amira Pharmaceuticals, Inc. announced it will present preclinical data on its program of LPA1 receptor antagonist on June 30, 2009 in the summer research conference of the Federation of American Societies for Experimental Biology (FASEB) held in Carefree, Arizona.

The LPA1 receptor is part of the phosphatidic acid path / lisofosfatidilcolina, which among other things is associated with the communication from cell to cell. In recent studies, it has been shown to play a role in fibrotic disease, particularly idiopathic pulmonary fibrosis (IPF).

ERYtech Pharma has been chosen to present the initial results obtained with its preclinical product GR-ARA1 on sickle cell anemia at the 50th annual congress of the American Society of Hematology (ASH), to be held in San Francisco (United States) from 6 to Dec. 9, 2008.

Sickle cell disease is a genetic disease characterized by the presence of sickle red blood cells in patients suffering from hypoxia (about 100,000 cases in Europe and North America).

ERYtech Pharma has been chosen to present the initial results obtained with its preclinical product GR-ARA1 on sickle cell anemia at the 50th annual congress of the American Society of Hematology (ASH), to be held in San Francisco (United States) from 6 to Dec. 9, 2008.

Sickle cell disease is a genetic disease characterized by the presence of sickle red blood cells in patients suffering from hypoxia (about 100,000 cases in Europe and North America).